Track topics on Twitter Track topics that are important to you
Danish drugmaker Novo Nordisk is collaborating with Kallyope, a US biotech focused on the gut-brain axis, to discover novel peptide therapeutics for obesity and diabetes. Kallyope has developed a platform to interrogate the gut-brain axis, which plays a significant role in appetite regulation and energy homoeostatis, and discover new medicines in multiple therapeutic areas.
Original Article: Novo Nordisk and Kallyope in Gut-Brain PactNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dictionary of Medicine). It is becoming increasing common i...